Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Nauck

Showing results (1-10 of 101) with videos related to

Pageof 11
Sort By:
Deutsche Medizinische Wochenschrift (1946)|February 26, 2011
[Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Pro]M A Nauck
Diabetologia|March 30, 1999
Is glucagon-like peptide 1 an incretin hormone?M A Nauck
Acta Diabetologica|December 5, 1998
Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspectiveM A Nauck
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|January 19, 2005
Glucagon-like peptide 1 (GLP-1) in the treatment of diabetesM A Nauck
Diabetes, Obesity & Metabolism|March 13, 2012
The design of the liraglutide clinical trial programmeM A Nauck
Clinical Chemistry and Laboratory Medicine|October 8, 1999
Six methods for the determination of C-peptide evaluatedM S Nauck, M A Nauck, M A Nauck, et al.
Deutsche Medizinische Wochenschrift (1946)|April 21, 2005
[Therapy with oral antidiabetic agents -- special considerations in the case of coronary heart disease]M A Nauck, S Matthaei
Gut|January 13, 2006
To be or not to be--an incretin or enterogastrone?M Horowitz, M A Nauck
Diabetic Medicine : a Journal of the British Diabetic Association|May 15, 2014
Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelines--a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problemsS Bauer, M A Nauck
Zeitschrift Fur Gastroenterologie|March 1, 1996
-Stumbling blocks in weight reduction--new genetic and metabolic hindrances in weight reduction-M A Nauck, W H Schmiegel
Pageof 11

Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
Deutsche Medizinische Wochenschrift (1946)|February 26, 2011
[Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Pro]M A Nauck
Diabetologia|March 30, 1999
Is glucagon-like peptide 1 an incretin hormone?M A Nauck
Acta Diabetologica|December 5, 1998
Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspectiveM A Nauck
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|January 19, 2005
Glucagon-like peptide 1 (GLP-1) in the treatment of diabetesM A Nauck
Diabetes, Obesity & Metabolism|March 13, 2012
The design of the liraglutide clinical trial programmeM A Nauck
Clinical Chemistry and Laboratory Medicine|October 8, 1999
Six methods for the determination of C-peptide evaluatedM S Nauck, M A Nauck, M A Nauck, et al.
Deutsche Medizinische Wochenschrift (1946)|April 21, 2005
[Therapy with oral antidiabetic agents -- special considerations in the case of coronary heart disease]M A Nauck, S Matthaei
Gut|January 13, 2006
To be or not to be--an incretin or enterogastrone?M Horowitz, M A Nauck
Diabetic Medicine : a Journal of the British Diabetic Association|May 15, 2014
Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelines--a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problemsS Bauer, M A Nauck
Zeitschrift Fur Gastroenterologie|March 1, 1996
-Stumbling blocks in weight reduction--new genetic and metabolic hindrances in weight reduction-M A Nauck, W H Schmiegel
Pageof 11